Results of CytoDyn’s PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials

Data Provide Support for PRO 140 as long-acting, HIV-1 maintenance therapy VANCOUVER, Washington, May 24, 2018 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB:CYDY) announces that results from its CD01 Phase 2b clinical trial and extension study showing the potential of PRO 140, its novel humanized CCR5 monoclonal antibody, as a long-acting, single-agent maintenance therapy for HIV-1 infected patients were published in the peer-reviewed journal HIV Clinical Trials. All HIV-1 infected patients enrolled in the CD01 Phase 2b trial exhibited suppressed viral load The post Results of CytoDyn’s PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials appeared first on Public Wire.
http://bit.ly/2INIU3z